Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 2, 1996, Pages 370-379

  Von Moltke, Lisa L ^a,b   Greenblatt, David J ^a,b   Harmatz, Jerold S ^a,b   Duan, Su Xiang ^a,b   Harrel, Lisa M ^a,b   Cotreau Bibbo, Monette M ^a,b   Pritchard, Gary A ^a,b   Wright, C Eugene ^c   Shader, Richard I ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450; HYPNOTIC SEDATIVE AGENT; KETOCONAZOLE; TRIAZOLAM;

ADULT; AGED; ANIMAL; ARTICLE; BIOTRANSFORMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERACTION; FEMALE; HUMAN; LIVER MICROSOME; MALE; METABOLISM; MIDDLE AGED; MOUSE; PHYSIOLOGY;

ADULT; AGED; ANIMALS; ANTIFUNGAL AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; KETOCONAZOLE; MALE; MICE; MICROSOMES, LIVER; MIDDLE AGED; TRIAZOLAM;

EID: 0030077245     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. ABERNETHY, D. R., GREENBLATT, D. J., DIVOLL, M., MOSCHITTO, L. J., HARMATZ, J. S. AND SHADER, R. I.: Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology 80: 275-278, 1983.
2. BACK, D. J., STEVENSON, P. AND TJIA, J. F.: Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br. J. Clin. Pharmacol. 28: 166-170, 1989.
3. BACK, D. J. AND TJIA, J. F.: Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol. 32: 624-626, 1991.
4. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S E. AND CHENERY, R. J.: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25: 261-270, 1995.
5. CHANG, T., LEVINE, M. AND BELLWARD, G. D : Selective inhibition of rat hepatic microsomal cytochrome P-450. II. Effect of the in vitro administration of cimetidine. J. Pharmacol. Exp. Ther. 260: 1450-1455, 1992.
6. COMO, J. A. AND DISMUKES, W. E.: Oral azole drugs as systemic antifungal therapy. N Engl. J. Med. 330: 263-272, 1994.
7. COX, S. R., KROBOTH, P. D., ANDERSON, P. H. AND SMITH, R. B.: Mechanism for the interaction between triazolam and cimetidine. Biopharm. Drug Dispos. 7: 567-575, 1986.
8. EBERTS, F. S., PHILOPOULOS, Y., REINEKE, L. M. AND VLIEK, R. W.: Triazolam disposition. Clin. Pharmacol. Ther. 29: 81-93, 1981.
9. ECHIZEN, H., KAWASAKI, H., CHIBA, K., TANI, M. AND ISHIZAKI, T.: A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J. Pharmacol. Exp. Ther. 264: 1425-1431, 1993.
10. FRIEDMAN, H., GREENBLATT, D. J., BURSTEIN, E. S., HARMATZ, J. S. AND SHADER, R. I.: Population study of triazolam pharmacokinetics. Br. J. Clin. Pharmacol. 22: 639-642, 1986
11. FRIEDMAN, H., GREENBLATT, D. J., BURSTEIN, E. S., SCAVONE, J. M., HARMATZ, J. S. AND SHADER, R. I.: Triazolam kinetics: Interaction with cimetidine, propranolol, and the combination. J. Clin. Pharmacol. 28: 228-233, 1988
12. FRIEDMAN, H , GREENBLATT, D J., PETERS, G. R., METZLER, C. M., CHARLTON, M. D., HARMATZ, J. S., ANTAL, E. J., SANBORN, E. C. AND FRANCOM, S. F.: Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time. Clin. Pharmacol. Ther. 52: 139-150, 1992.
13. GASCON, M. P. AND DAYER, P.: In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur. J Clin. Pharmacol. 41: 573-578, 1991.
14. GOMEZ, D., WACHER, V. J., TOMLANOVICH, S. J., HEBERT, M. AND BENET, L. Z.: The effect of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 88: 15-19, 1995.
15. GREENBLATT, D. J., EHRENBERG, B. L., GUNDERMAN, J., LOCNISKAR, A., SCAVONE, J. M., HARMATZ, J. S. AND SHADER, R. I.: Pharmacokinetic and electroencepha-lographic study of intravenous diazepam, midazolam, and placebo. Clin. Pharmacol Ther. 45: 356-365, 1989a.
16. GREENBLATT, D. J., EHRENBERG, B. L., GUNDERMAN, J., SCAVONE, J. M., TAI, N. T., HARMATZ, J. S. AND SHADER, R. I.: Kinetic and dynamic study of intravenous lorazepam: Comparison with intravenous diazepam. J. Pharmacol. Exp. Ther. 250: 134-140, 1989b.
17. GREENBLATT, D. J , HARMATZ, J. S., GOUTHRO, T A., LOCKE, J. AND SHADER, R I : Distinguishing a benzodiazepine agonist (triazolam) from a non-agonist anxiolytic (buspirone) by electroencephalography: Kinetic-dynamic studies. Clin. Pharmacol. Ther. 56: 100-111, 1994.
18. GREENBLATT, D. J., HARMATZ, J S., SHAPIRO, L., ENGELHARDT, N., GOUTHRO, T. A. AND SHADER, R. I.: Sensitivity to triazolam in the elderly. N. Engl. J. Med. 324: 1691-1698, 1991.
19. GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., CIRAULO, D. A. AND SHADER, R. I.: Alprazolam pharmacokinetics, metabolism, and plasma levels: Clinical implications. J. Clin Psychiatry 54: (October Supp.) 4-11, 1993.
20. GREENE, D. S., DOCKENS, R. C., SALAZAR, D. E. AND BARBHAIYA, R. H.: Coadministration of nefazodone (NEF) and benzodiazopines. 1. Pharmacokinetic assessment. Clin. Pharmacol. Ther 55: 141, 1994.
21. HALPERT, J. R.: Structural basis of selective cytochrome P450 inhibition. Annu. Rev. Pharmacol. Toxicol. 35: 29-53, 1995.
22. HEBERT, M. F., ROBERTS, J. P., PRUEKSARITANONT, T. AND BENET, L. Z.: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Thor. 52: 453-457, 1992.
23. HOUSTON, J. B.: Utility of In vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47: 1469-1479, 1994.
24. INOUE, T. AND SUZUKI, S.-I.: High-performance liquid chromatographic determination of triazolam and its metabolites in human urine. J. Chromatogr. 422: 197-204, 1987.
25. JURIMA-ROMET, M., CRAWFORD, K., CYR, T. AND INABA, T.: Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 22: 849-857, 1994.
26. KOLARS, J. C., AWNI, W. M., MERION, R. M. AND WATKINS, P. B.: First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488-1490, 1991.
27. KOLARS, J. C., LOWN, K. S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERION, R M AND WATKINS, P. B : CYP3A gene expression in human gut epithelium. Pharmacogenetics 4: 247-259, 1994.
28. KOLARS, J. C., SCHMIEDLIN-REN, P., SCHUETZ, J. D., FANG, C. AND WATKINS, P. B.: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90: 1871-1878, 1992
29. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. AND MEYER, U. A.: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36: 89-96, 1989.
30. KROBOTH, P. D., MCAULEY, J. W., KROBOTH, F. J., BERTZ, R. J. AND SMITH, R. B.: Triazolam pharmacokinetics after intravenous, oral and sublingual administration. J. Clin. Psychopharmacol. 15: 259-262, 1995.
31. LING, K.-H. J., LEESON, G. A., BURMASTER, S. D., HOOK, R. H., REITH, M. K. AND CHENG, L. K.: Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab. Dispos. 23: 631-636, 1995.
32. LOWN, K. S., KOLARS, J. C., THUMMEL, K E., BARNETT, J. L., KUNZE, K. L., WRIGHTON, S. A. AND WATKINS, P. B.: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22: 947-955, 1994.
33. MATTHEW, D., BRENNAN, B., ZOMORODI, K. AND HOUSTON, J. B.: Disposition of azole antifungal agents 1. Nonlinearities in ketoconazole clearance and binding in rat liver. Pharmaceut. Res 10: 418-422, 1993.
34. NEWTON, D. J., WANG, R. W. AND LU, Y. H.: Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23: 154-158, 1995.
35. PASERCHIA, L. A., HEWETT, J. AND WOOSLEY, R. L.: Effects of ketoconazole on QTC. Clin. Pharmacol. Ther. 55: 146, 1994.
36. PHILLIPS, J. P , ANTAL, E. J AND SMITH, R. B.: A pharmacokinetic drug interaction between erythromycin and triazolam. J. Clin. Psychopharmacol. 6: 297-299, 1986.
37. PHULL, R K., GREENBLATT, D. J , VON MOLTKE, L. L., HARMATZ, J. S. AND SHADER, R. I : Diazepam biotransformation in vitro: Species differences and effects of inhibitors. Clin. Pharmacol. Ther. 57: 205, 1995.
38. POURBAIX, S., DESAGER, J. P., HULHOVEN, R., SMITH, R. B. AND RARVENGT, C.: Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int. J. Chn. Pharmacol. Ther. Toxicol. 23: 447-451, 1985.
39. RASMUSSEN, B B., MAENPAA, J., PELKONEN, O., LOFT, S., POULSEN, H. E., LYKKESFELDT, J AND BRØSEN, K.: Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine Br. J. Clin. Pharmacol. 39: 151-159, 1995.
40. RILEY, C. M AND JAMES, M O.: Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J. Chromatogr. 377: 287-294, 1986.
41. RODRIGUES, A. D., MULFORD, D. J., LEE, R. D., SURBER, B. W., KUKULKA, M. J., FERRERO, J. L., THOMAS, S. B., SHET, M. S. AND ESTABROOK, R. W.: In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab. Dispos. 23: 765-775, 1995.
42. ROOS, P. H., GOLUB-CIOSK, B., KALLWEIT, P., KAUCZINSKI, D. AND HANSTEIN, W. G.: Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450 isozymes. Biochem. Pharmacol. 45: 2239-2250, 1993.
43. SCHMIDER, J., GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S. AND SHADER, R. I.: N-demethylation of amitriptyline in vitro: Role of cytochrome P450-3A (CYP3A) isoforms, and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 275: 592-597, 1995.
44. SEGEL, I. H.: Biochemical Calculations, 2nd ed., John Wiley, New York, 1976.
45. SENDA, N., KOHTA, K., TAKAHASHI, T., SHIZUKUISHI, K., MIMURA, T., FUJITA, T. AND NAKAYAMA, M.: A highly sensitive method to quantify triazolam and its metabolites with liquid chromatography-mass spectrometry. Biomed. Chromatogr. 9: 48-51, 1995.
46. SETHY, V. H. AND HARRIS, D. W.: Determination of biological activity of alprazolam, triazolam and their metabolites. J. Pharm. Pharmacol. 34: 115-116, 1982.
47. SHADER, R. I., DREYFUSS, D., GERREIN, J. R., HARMATZ, J. S., ALLISON, S. J. AND GREENBLATT, D. J.: Sedative effects and impaired learning and recall following single oral doses of lorazepam. Clin. Pharmacol. Ther. 39: 526-529, 1986.
48. 1 for conventional and alternatesubstrate inhibitors. Biochem. Pharmacol. 30: 1-7, 1981.
49. SWINNEY, D. C.: Progesterone metabolism in hepatic microsomes. Drug Metab. Dispos. 18: 859-865, 1990.
50. TUCKER, G. T.: The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Int. J. Clin. Pharmacol Ther. Toxicol. 30: 550-553, 1992.
51. VANDERVEEN, R. P., JIRAK, J. L., PETERS, G. R., COX, S. R. AND BOMBARDT, P. A.: Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin. Pharmacol. 10: 539-543, 1991.
52. VARHE, A., OLKKOLA, K. T. AND NEUVONEN, P. J.. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56: 601-607, 1994.
53. VON MOLTKE, L. L., GREENBLATT, D. J., COURT, M. H., DUAN, S. X., HARMATZ, H. S. AND SHADER, R. I.: Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotomn reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15: 125-131, 1995a.
54. VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., DUAN, S. X., HARMATZ, J. S. AND SHADER, R I.: Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J. Pharmacol. Exp Ther 268: 1278-1283, 1994a.
55. VON MOLTKE, L. L., GEEENBLATT, D. J , COTREAU-BIBBO, M. M., HARMATZ, J. S. AND SHADER, R. I.: Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol. 38: 23-31, 1994b.
56. VON MOLTKE, L. L., GREENBLATT, D. J., DUAN, S. X., HARMATZ, J. S. AND SHADER, R. I.: In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol. 34: 1222-1227, 1994c.
57. VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S. AND SHADER, R. I : Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47: 268-276, 1993.
58. VON MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., HARMATZ, J. S. AND SHADER, R. I.: Metabolism of drugs by Cytochrome P450-3A isoforms: Implications for drug interactions in psychopharmacology Clin Pharmacokinet. 29: Suppl. 1, 33-43, 1995b.
59. WAROT, D., BERGOUGNAN, L., LAMIABLE, D , BERLIN, I., BENSIMON, G., DANJOU, P. AND PUECH, A. J : Troleandomycin-triazolam interaction in healthy volunteers: Pharmacokinetic and psychometric evaluation. Eur. J. Clin. Pharmacol. 32: 389-393, 1987.
60. WRIGHT, C. E., LASHER-SISSON, T. A., STEENWYK, R. C. AND SWANSON, C. N.: A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 12: 103-106, 1992.
61. WRIGHTON, S. A AND RING, B. J.: Inhibition of human CYP3A catalyzed 1′-hydroxy-midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceut. Res. 11: 921-924, 1994.